Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms GMB-101 |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H47F3N8O7S |
InChIKeyDTXGFSWBHDABPE-MNYREFGISA-N |
CAS Registry2489876-12-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | United States | 13 Sep 2019 |